Medications for treatment of breast cancer belong to four categories. First category is of ant metabolites which inhibits action of metabolite as these compounds are similar in structurally to metabolites. Medications belonging to this category are 5 fluorouracil and methothrexate. Second categories of medication are antibiotics like doxorubicin and epirubicin. Third categories of medications are inhibitors of microtubule formation like paclitaxel which belong to taxol group. Forth category of medication is alkylating agents like cyclophosphamide. All these medicatins act differently. Alkylating agents like cyclophosphamide gets activated in liver by cyt p450 enzyme and leads to alkylation of DNA. Antibiotic like doxorubicin acts by intracting with molecular oxygen leading to formation of superoxide and hydrogen peroxide which ultimately leads to single step breakdown of DNA. Taxol group act by binding reversibly to beta tubulin and leads to over stabalization of beta tubulin which is non functionalthis result in cell death of infected cells. All treatment possesses a number of side effects. Cyclophosphamide causes bone marrow depression. Paclitaxel causes neutropenia that is decrease in number of neutrophils. Methothrexate shows renal damage, hepatic function alteration and pulmonary toxicity. Fluoro uracil shows bone marrow depression as major toxicity.
In 1987, the center began exploring possible new homes to replace its 9-building campus on First Hill that it was set to outgrow.   A site in the South Lake Union neighborhood, envisioned by the city as a future high-tech and biotechnology hub,  was chosen in September 1988 after a deal to move to Fremont fell through earlier that year.   The first phase of the campus, designed by firm Zimmer Gunsul Frasca Partnership ,  began construction in 1991 and opened on June 1, 1993 in a ceremony that included the burying of a time capsule set to open in 2093.